These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22352892)

  • 1. Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases.
    Nguyen TB; Lozach O; Surpateanu G; Wang Q; Retailleau P; Iorga BI; Meijer L; Guéritte F
    J Med Chem; 2012 Mar; 55(6):2811-9. PubMed ID: 22352892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new fluorescent xanthines as kinase inhibitors.
    Kim D; Jun H; Lee H; Hong SS; Hong S
    Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide.
    Conchon E; Anizon F; Aboab B; Prudhomme M
    J Med Chem; 2007 Sep; 50(19):4669-80. PubMed ID: 17722905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin.
    Tannert R; Milroy LG; Ellinger B; Hu TS; Arndt HD; Waldmann H
    J Am Chem Soc; 2010 Mar; 132(9):3063-77. PubMed ID: 20148556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of B-ring analogues of (-)-rhazinilam.
    Décor A; Monse B; Martin MT; Chiaroni A; Thoret S; Guénard D; Guéritte F; Baudoin O
    Bioorg Med Chem; 2006 Apr; 14(7):2314-32. PubMed ID: 16314101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A series of natural flavonoids as thrombin inhibitors: structure-activity relationships.
    Liu L; Ma H; Yang N; Tang Y; Guo J; Tao W; Duan J
    Thromb Res; 2010 Nov; 126(5):e365-78. PubMed ID: 20828797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors.
    Debdab M; Renault S; Lozach O; Meijer L; Paquin L; Carreaux F; Bazureau JP
    Eur J Med Chem; 2010 Feb; 45(2):805-10. PubMed ID: 19879673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the target differentiation potential of imidazole-based protein kinase inhibitors.
    Dimova D; Iyer P; Vogt M; Totzke F; Kubbutat MH; Schächtele C; Laufer S; Bajorath J
    J Med Chem; 2012 Dec; 55(24):11067-71. PubMed ID: 23210446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent ITK inhibitors through focused compound library design including structural information.
    Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis.
    Lavrard H; Rodriguez F; Delfourne E
    Bioorg Med Chem; 2014 Sep; 22(17):4961-7. PubMed ID: 25047935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of C-ring aromatized analogues of phenanthridone alkaloids.
    Lee S; Hwang S; Yu S; Jang W; Lee YM; Kim S
    Arch Pharm Res; 2011 Jul; 34(7):1065-70. PubMed ID: 21811912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation.
    Liu T; Xu Z; He Q; Chen Y; Yang B; Hu Y
    Bioorg Med Chem Lett; 2007 Jan; 17(1):278-81. PubMed ID: 17085048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stereodivergent strategy for the preparation of corynantheine and ipecac alkaloids, their epimers, and analogues: efficient total synthesis of (-)-dihydrocorynantheol, (-)-corynantheol, (-)-protoemetinol, (-)-corynantheal, (-)-protoemetine, and related natural and nonnatural compounds.
    Zhang W; Bah J; Wohlfarth A; Franzén J
    Chemistry; 2011 Dec; 17(49):13814-24. PubMed ID: 22052788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.